GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » Operating Income

MYND Life Sciences (XCNQ:MYND) Operating Income : C$-1.29 Mil (TTM As of Jul. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences Operating Income?

MYND Life Sciences's Operating Income for the three months ended in Jul. 2024 was C$-0.34 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jul. 2024 was C$-1.29 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. MYND Life Sciences's Operating Income for the three months ended in Jul. 2024 was C$-0.34 Mil. MYND Life Sciences's Revenue for the three months ended in Jul. 2024 was C$0.00 Mil. Therefore, MYND Life Sciences's Operating Margin % for the quarter that ended in Jul. 2024 was %.

MYND Life Sciences's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MYND Life Sciences's annualized ROC % for the quarter that ended in Jul. 2024 was -44.78%. MYND Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2024 was -27,360.00%.


MYND Life Sciences Operating Income Historical Data

The historical data trend for MYND Life Sciences's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences Operating Income Chart

MYND Life Sciences Annual Data
Trend Oct21 Oct22 Oct23
Operating Income
-4.29 -3.06 -1.83

MYND Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.39 -0.33 -0.22 -0.34

MYND Life Sciences Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MYND Life Sciences  (XCNQ:MYND) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MYND Life Sciences's annualized ROC % for the quarter that ended in Jul. 2024 is calculated as:

ROC % (Q: Jul. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Apr. 2024 ) + Invested Capital (Q: Jul. 2024 ))/ count )
=-1.368 * ( 1 - 0% )/( (3.005 + 3.105)/ 2 )
=-1.368/3.055
=-44.78 %

where

Note: The Operating Income data used here is four times the quarterly (Jul. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

MYND Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jul. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Apr. 2024  Q: Jul. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.368/( ( (0.005 + max(-2.616, 0)) + (0.005 + max(-3.095, 0)) )/ 2 )
=-1.368/( ( 0.005 + 0.005 )/ 2 )
=-1.368/0.005
=-27,360.00 %

where Working Capital is:

Working Capital(Q: Apr. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.69 + 0 + 0.011) - (3.317 + 0 + 0)
=-2.616

Working Capital(Q: Jul. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.604 + 0 + 0.009) - (3.708 + 0 + 0)
=-3.095

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jul. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

MYND Life Sciences's Operating Margin % for the quarter that ended in Jul. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jul. 2024 )/Revenue (Q: Jul. 2024 )
=-0.342/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


MYND Life Sciences Operating Income Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


MYND Life Sciences Business Description

Traded in Other Exchanges
Address
105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2
MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.